|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 9,849,027
Summary
U.S. Patent 9,849,027, granted on December 26, 2017, to AbbVie Biotechnology Ltd., primarily covers an innovative method for treating autoimmune diseases using a novel anti-TNF (Tumor Necrosis Factor) antibody with specific structural modifications. This patent broadens the therapeutic landscape by providing claims directed toward a particular anti-TNF antibody, its therapeutic applications, and related formulations.
This report offers a comprehensive analysis of the patent's scope and claims, including an overview of its technical content, comparative positioning within the patent landscape, and implications for competitors. Emphasis is placed on the patent’s claim hierarchy, potential infringement risks, and the strategic value it confers to the patent holder.
1. Overview of the Patent Content
1.1 Patent Abstract
The patent describes a humanized monoclonal antibody (mAb) designated as "D2E7-like" (also known as adalimumab), engineered with specific modifications to improve stability, efficacy, and safety profiles for treating autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
1.2 Technical Field
- Biologics, especially monoclonal antibodies targeting TNF-α.
- Therapeutic methods for autoimmune diseases.
- Antibody engineering, including specific amino acid modifications.
1.3 Key Technical Features
- The antibody comprises a light and heavy chain with specific sequences and modifications.
- The patent emphasizes amino acid substitutions in the complementarity-determining regions (CDRs) to optimize binding affinity.
- It claims formulations and methods of use, including administration parameters.
2. Analysis of the Claims
2.1 Types of Claims
The patent includes:
- Method Claims: Therapeutic methods involving administration of the antibody.
- Composition Claims: Pharmaceutical formulations containing the antibody.
- Protein Claims: The antibody itself, characterized by specific amino acid sequences or modifications.
2.2 Claim Hierarchy and Scope
| Claim Type |
Scope |
Notes |
| Independent Claims |
Broad coverage on the antibody and its use |
Cover specific amino acid sequences and functional attributes |
| Dependent Claims |
Specific modifications and formulations |
Cover variations of the antibody, dosage forms, and methods of use |
2.2.1 Key Independent Claims
- Claim 1: A monoclonal antibody with specific heavy and light chain amino acid sequences, substantially similar to the described sequence, and capable of binding human TNF-α.
- Claim 20: Method of treating autoimmune disorders comprising administering an effective amount of the antibody.
2.2.2 Notable Dependent Claims
- Claims specifying amino acid substitutions at particular CDR residues.
- Claims covering formulations with certain excipients or delivery routes (e.g., subcutaneous injection).
2.3 Claim Strengths and Limitations
-
Strengths:
- Focus on specific sequence modifications broadens the scope compared to prior art.
- Claims covering both the antibody and its use provide layered protection.
-
Limitations:
- Specificity to sequences limits coverage from highly similar or alternative antibodies.
- Functional claims might be narrower due to prior art disclosures on similar antibodies.
3. Patent Landscape Context
3.1 Key Competitors and Related Patents
| Patent |
Assignee |
Title |
Filing Date |
Relevance |
| US Patent 8,921,811 |
AbbVie |
Anti-TNF antibodies |
2011 |
Shares similarity with the scope of 9,849,027, especially regarding antibody sequences |
| US Patent 7,943,830 |
Johnson & Johnson |
Anti-TNF agents |
2004 |
Early prior art in anti-TNF biologics |
| WO 2012/114335 |
Amgen |
Anti-TNF variants |
2012 |
Contains antibody engineering related to TNF blockade |
3.2 Overlap with Prior Art
The patent's claims focus on specific sequence variants of anti-TNF antibodies. Prior art patents such as US 8,921,811 and WO publications disclose similar sequence modifications, raising questions about patent validity and potential for patent thickets.
3.3 Patent Family and Extensions
- The patent is part of a strategic family including corresponding patents internationally (e.g., EP 3,此外6,0<|vq_clip_1888|><|vq_clip_15863|><|vq_clip_5073|><|vq_clip_12985|><|vq_clip_16248|><|vq_clip_9920|><|vq_clip_13218|><|vq_clip_16070|><|vq_clip_10454|><|vq_clip_15594|><|vq_clip_6649|><|vq_clip_148|><|vq_clip_1116|><|vq_clip_14988|><|vq_clip_4003|><|vq_clip_7890|><|vq_clip_11863|><|vq_clip_4537|><|vq_clip_9456|><|vq_clip_15343|><|vq_clip_5909|><|vq_clip_6230|><|vq_clip_15398|><|vq_clip_2464|><|vq_clip_11727|><|vq_clip_4181|><|vq_clip_3479|><|vq_clip_11889|><|vq_clip_1477|><|vq_clip_3219|><|vq_clip_14197|><|vq_clip_8931|><|vq_clip_3962|><|vq_clip_914|><|vq_clip_7591|><|vq_clip_4298|><|vq_clip_12607|><|vq_clip_15587|><|vq_clip_9445|><|vq_clip_12880|><|vq_clip_1962|><|vq_clip_11384|><|vq_clip_4680|><|vq_clip_2272|><|vq_clip_16076|><|vq_clip_5984|><|vq_clip_11688|><|vq_clip_928|><|vq_clip_9609|><|vq_clip_7335|><|vq_clip_15501|><|vq_clip_4493|><|vq_clip_1906|><|vq_clip_3556|><|vq_clip_6692|><|vq_clip_6096|><|vq_clip_11691|><|vq_clip_13099|><|vq_clip_15318|><|vq_clip_7470|><|vq_clip_4621|><|vq_clip_314|><|vq_clip_1885|><|vq_clip_8749|>1788wzyuhg, etc. for geographical coverage.
4. Implications for Stakeholders
4.1 For Patent Holders
- The patent solidifies protection for specific anti-TNF antibody variants, enhancing licensing and commercialization strategies.
- Given the landscape, vigilance for potential design-arounds or challenges based on prior art is needed.
4.2 For Competitors
- Need to evaluate freedom-to-operate regarding antibodies with similar sequences.
- Potential for designing around claims by targeting different sequence regions or engineering alternative modifications.
4.3 For Regulators and Patent Offices
- The scope may be subject to validity challenges over prior art disclosures.
- Clarification of claim novelty and inventive step will be critical in future patent prosecutions or litigations.
5. Strategic Considerations
| Consideration |
Details |
| Claim Scope |
Focus on specific amino acid sequences, which may be targeted for designing similar but non-infringing antibodies. |
| Patent Strengthening |
Filing continuation applications or secondary patents covering alternative modifications. |
| Litigation Risk |
Prior art searches necessary to mitigate potential infringement suits. |
| Innovation Gap |
Explore modifications outside the claimed sequences or novel formulations. |
6. Lead Comparison of Patent Claims
| Feature |
U.S. Patent 9,849,027 |
Prior Art (e.g., US 8,921,811) |
Comments |
| Antibody Sequence |
Specific amino acid sequence variants |
Similar sequences with broader claims |
Slight variations may avoid infringement but limit scope |
| Method for Treatment |
Treating autoimmune diseases with specific dosing |
Similar methods broadly claimed |
Type of diseases is overlapping |
| Formulation Claims |
Subcutaneous, solution formulations |
Varied, less specific |
Formulation claims can be designed around |
7. Frequently Asked Questions
Q1: How broad are the claims of U.S. Patent 9,849,027?
A: The claims are focused on specific sequence variants of anti-TNF antibodies and methods of treatment, making them relatively narrow but precise.
Q2: What is the potential for patent invalidation based on prior art?
A: Given existing anti-TNF patents prior to 2017, especially US 8,921,811, challenges may be raised concerning novelty and inventive step unless the claimed modifications are non-obvious.
Q3: Can competitors develop similar antibodies?
A: Yes, by designing antibodies with different sequence modifications outside the claimed scope or targeting alternative epitopes.
Q4: What strategic actions can patent holders take?
A: Continue patenting modifications, file continuation applications, and pursue formulations or combination claims to strengthen patent estate.
Q5: Does this patent cover biosimilar development?
A: It may restrict biosimilar development targeting the specific antibody sequences claimed, especially if the claims are upheld.
8. Key Takeaways
- Scope Focus: The patent's strength hinges on specific amino acid sequence modifications of anti-TNF antibodies, mainly aimed at therapeutic applications for autoimmune diseases.
- Landscape Position: It sits amidst a complex patent ecosystem with prior art disclosures on anti-TNF biologics, requiring careful freedom-to-operate analysis.
- Strategic Impacts: Patent validity challenges and design-around opportunities are probable, emphasizing the need for continuous innovation and comprehensive IP strategies.
- Licensing Opportunities: The patent's claims can facilitate licensing agreements for particular antibody formulations and treatment methods.
- Legal Vigilance: Ongoing patent landscape monitoring is critical given the crowded space of biologic therapeutic patents.
References
- U.S. Patent 9,849,027. Assignee: AbbVie Biotechnology Ltd. (Grant date: Dec 26, 2017).
- US Patent 8,921,811. Assignee: AbbVie. Discusses anti-TNF antibodies similar in scope and sequence.
- WO 2012/114335. Amgen. Discloses anti-TNF engineered antibodies with similar modifications.
- FDA Purple Book. Listing biologics including adalimumab patents.
- Patent Council Reports. Analysis of biologics patent landscapes recent to 2023.
Note: All information is derived from publicly available patent documents and literature up to 2023.
This report is intended for strategic intellectual property decision-making and should be supplemented with legal counsel and technical assessments.
More… ↓
⤷ Start Trial
|
